Entyvio, Stelara plus immunomodulators not as effective for IBD Disclosures: Lutz reports no relevant disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Back to Healio
Neither Entyvio nor Stelara plus immunomodulators were as effective as other therapies for inflammatory bowel disease, according to research at Digestive Disease Week.
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population
Poster of Distinction Award Granted to TARGET-IBD Research
News provided by
Share this article
Share this article
DURHAM, N.C., May 23, 2021 /PRNewswire/ Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Target RWE s TARGET-IBD large longitudinal cohort
Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real World Cohort was selected for the Poster of Distinction Award.